



Press release

## Major order from India

Bactiguard has received a major order from India of some 50 000 Foleys for infection prevention. At the same time, the planned clinical study has been initiated.

The first order from India consists of some 50 000 Foley catheters for infection protection (BIP Foleys) and generates direct sales revenues of close to 2 million SEK, at product delivery.

We are delighted that we can now start penetrating the Indian market for real. The
problem of healthcare associated infections is huge, particularly in India, where the
largest consumption of antibiotics in the world has led to a high level of multi-resistant
bacteria. This means that there is an urgent need for preventive solutions, says
Cecilia Edström, Director of Sales & New Business.

In parallel, the planned clinical study, involving 1 000 patients in total, has been initiated. The study will be conducted at six prestigious hospitals in different regions of the country and will be a powerful marketing tool in India.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 9 December 2015, at 08.00

## For further information, please contact:

Ulrika Berglund, Head of External Affairs, mobile: +46 708 800 407

## **About Bactiguard**

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, Latin America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters are located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at <a href="https://www.bactiguard.com">www.bactiguard.com</a>.